All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), anti-PD-(L)1 vs. platinum association, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DANUBE (D vs C - all population), 2020 0.99 [0.83; 1.18]
DANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.02 [0.83; 1.25]
KEYNOTE-361 (PC vs C), 2021 0.86 [0.72; 1.02]
0.94 [0.85 ; 1.03 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 4 0% 2,569 moderate not evaluable progression or deaths (PFS)detailed results DANUBE (D vs C - all population), 2020 0.77 [0.54; 1.09]
DANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08]
KEYNOTE-361 (PC vs C), 2021 0.78 [0.65; 0.93]
0.83 [0.67 ; 1.03 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, KEYNOTE-361 (PC vs C), 2021 3 31% 1,809 moderate not evaluable DORdetailed results DANUBE (D vs C - all population), 2020 0.35 [0.20; 0.62]
DANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.21 [0.12; 0.37]
0.27 [0.19 ; 0.38 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020 3 0% 672 moderate not evaluable objective responses (ORR)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.26; 0.49]
DANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.38 [0.28; 0.53]
KEYNOTE-361 (PC vs C), 2021 1.48 [1.10; 2.00]
0.54 [0.26 ; 1.11 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 4 95% 2,569 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.14 [0.05; 0.40]
0.14 [0.05 ; 0.40 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable AE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.37 [0.27; 0.52]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.12 [0.08; 0.17]
0.21 [0.07 ; 0.65 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020 2 95% 1,402 moderate not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (PC vs C), 2021 1.53 [1.01; 2.33]
1.53 [1.01 ; 2.33 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.59 [0.88; 2.87]
KEYNOTE-361 (PC vs C), 2021 3.74 [1.75; 7.95]
2.36 [1.02 ; 5.43 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 2 67% 1,435 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.66 [0.43; 1.03]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.13 [0.08; 0.21]
KEYNOTE-361 (PC vs C), 2021 2.02 [1.42; 2.89]
0.56 [0.12 ; 2.66 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 98% 2,105 moderate not evaluable SAE (any grade)detailed results DANUBE (D vs C - all population), 2020 1.01 [0.74; 1.39]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.78 [0.59; 1.05]
0.89 [0.69 ; 1.14 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020 2 29% 1,402 moderate not evaluable STRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.50 [0.31; 0.81]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.41 [0.28; 0.60]
KEYNOTE-361 (PC vs C), 2021 1.16 [0.83; 1.61]
0.62 [0.31 ; 1.24 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 89% 2,093 moderate not evaluable TRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.13 [0.09; 0.21]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.04; 0.11]
0.10 [0.05 ; 0.19 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020 2 75% 1,402 moderate not evaluable TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.10 [0.07; 0.15]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.04 [0.03; 0.06]
KEYNOTE-361 (PC vs C), 2021 1.19 [0.85; 1.67]
0.18 [0.02 ; 1.31 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 99% 2,093 moderate not evaluable TRAE leading to death (grade 5)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.16; 20.16]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.82 [0.18; 3.71]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.14; 7.00]
1.01 [0.35 ; 2.96 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 0% 2,093 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.46 [0.26; 0.79]
0.46 [0.26 ; 0.79 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.41 [0.11 ; 18.39 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Anaemia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.05 [0.02; 0.13]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.02; 0.30]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.63; 1.20]
0.15 [0.02 ; 1.38 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 95% 2,093 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Arthritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Asthenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.25 [0.05; 1.24]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.63 [0.18; 2.15]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.38; 2.50]
0.66 [0.33 ; 1.33 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 4% 2,093 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Colitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 1.97 [0.18; 21.78]
1.59 [0.20 ; 12.37 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Constipation TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 0.24 [0.01; 5.43]
0.40 [0.04 ; 4.61 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.68 [0.15; 3.05]
IMvigor-130 (At-arm B vs Ch-armC), 2020 2.21 [0.20; 24.48]
KEYNOTE-361 (PC vs C), 2021 0.32 [0.03; 3.14]
0.73 [0.24 ; 2.22 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 0% 2,093 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.41 [0.11 ; 18.39 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.07; 1.86]
KEYNOTE-361 (PC vs C), 2021 1.38 [0.43; 4.39]
0.80 [0.22 ; 2.93 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 42% 1,349 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Fatigue TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 0.89]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.73 [0.12; 4.41]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.33; 2.28]
0.54 [0.18 ; 1.62 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 36% 2,093 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.15 [0.01; 3.01]
0.15 [0.01 ; 3.01 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Gastritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 5.48 [0.27; 109.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
3.50 [0.37 ; 33.12 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.41 [0.11 ; 18.39 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
2.97 [0.27 ; 32.10 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.24 [0.20 ; 25.51 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.13; 6.48]
0.91 [0.13 ; 6.48 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 2.74 [0.28; 26.45]
2.74 [0.28 ; 26.45 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 6.46 [0.79; 52.82]
6.46 [0.79 ; 52.82 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.04 [0.00; 0.62]
KEYNOTE-361 (PC vs C), 2021 0.68 [0.38; 1.24]
0.22 [0.01 ; 3.62 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 75% 1,349 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.75 [0.28 ; 27.20 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Myositis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.39 [0.11 ; 18.19 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Nausea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.06 [0.00; 0.97]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.27 [0.01; 6.11]
KEYNOTE-361 (PC vs C), 2021 0.85 [0.31; 2.38]
0.37 [0.07 ; 1.86 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 41% 2,093 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.75 [0.28 ; 27.20 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.01 [0.00; 0.09]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.03 [0.00; 0.52]
KEYNOTE-361 (PC vs C), 2021 0.94 [0.67; 1.32]
0.07 [0.00 ; 2.30 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 89% 2,093 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.24 [0.20 ; 25.51 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 2.13]
0.11 [0.01 ; 2.13 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-361 (PC vs C), 2021 2.96 [0.31; 28.57]
3.18 [0.51 ; 19.85 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pruritus TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.10 [0.02; 55.68]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
2.65 [0.38 ; 18.62 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 0% 2,093 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.23 [0.01; 5.02]
0.23 [0.01 ; 5.02 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
IMvigor-130 (At-arm B vs Ch-armC), 2020 4.43 [0.20; 98.49]
KEYNOTE-361 (PC vs C), 2021 3.95 [0.44; 35.56]
3.98 [0.84 ; 18.82 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 0% 2,093 moderate not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.98 [0.02 ; 49.53 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Sepsis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.06; 14.56]
0.91 [0.06 ; 14.56 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 3.99 [0.84; 18.92]
3.99 [0.84 ; 18.92 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.02 [0.00; 0.29]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
KEYNOTE-361 (PC vs C), 2021 0.80 [0.52; 1.24]
0.14 [0.01 ; 1.49 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (PC vs C), 2021 3 83% 2,093 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.94 [0.06 ; 15.11 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 0% 1,349 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.09 [0.00; 1.64]
KEYNOTE-361 (PC vs C), 2021 1.11 [0.42; 2.90]
0.46 [0.04 ; 4.83 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (PC vs C), 2021 2 61% 1,349 moderate not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.05; 0.13]
0.08 [0.05 ; 0.13 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.51 [0.24; 1.10]
0.51 [0.24 ; 1.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.22 [0.09; 0.54]
0.22 [0.09 ; 0.54 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.05 [0.00; 0.92]
0.05 [0.00 ; 0.92 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.54 [0.18; 1.61]
0.54 [0.18 ; 1.61 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.25 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
0.08 [0.01 ; 0.58 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Neutropenia AE (grade 3-4)detailed results Out of scale IMvigor-130 (At-arm B vs Ch-armC), 2020 0.00 [0.00; 0.05]
0.00 [0.00 ; 0.05 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.10 [0.01; 0.76]
0.10 [0.01 ; 0.76 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 09:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563